Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
A novel form of azithromycin and processes for preparation of pure azithromycin monohydrate isopropanol clathrate (3 molecules of isopropanol for every 10 molecules of azithromycin monohydrate) has been obtained. Preparation of the novel form of azithromycin comprises the steps of dissolving azithromycin in isopropanol, followed by the slow addition of water to the organic solution.
Latest Apotex, Inc. Patents:
This invention relates to a new form of azithromycin, namely azithromycin monohydrate isopropanol clathrate, which has improved properties over amorphous azithromycin, azithromycin monohydrate and azithromycin dihydrate. This invention also relates processes for the manufacture of azithromycin monohydrate isopropanol clathrate.
BACKGROUND OF THE INVENTIONAzithromycin, 9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, is a semi-synthetic macrolide antibiotic which can be classified as a member of the second-generation erythromycin antibacterial agent. Azithromycin has the following structure (I):
The spectrum of azithromycin's antibacterial activity has been reported by Aronoff, et al (J. Antimicrob. Chemother, 1987, 19, 275). Its mode of action has been reviewed by Retsema, et al (Antimicrob. Ag. Chemother, 1987, 31, 1939)n, and its pharmacology has been reviewed by a number of investigators (J. Antimicrob. Chemother., 1993, 31, Suppl. E, 1-198).
Three forms of Azithromycin are known. Anhydrous azithromycin is reported as an amorphous crude product (foam) in Canadian Patent 1 191 843 (example 1). It is obtained by evaporating the final solvent (e.g. chloroform) used in the process of preparation of azithromycin. It is not a crystalline product and therefore can not be made in pure form per se in commercial scale. In laboratory scale, it can be obtained in pure form by chromatography of the crude final product or by dissolving pure crystalline azithromycin mono- or dihydrate in an organic solvent and evaporating the said solvent to obtain amorphous anhydrous azithromycin.
Canadian patents 1,202,620, 1,202,619, 1,202,963 and 1,314,876 teach the process of making azithromycin monohydrate but do not claim the resulting product. Furthermore, these patents do not provide a description of the drying process (temperature or pressure). Canadian patents 1,191,843 and 1,202,963 claim azithromycin monohydrate as a new form of azithromycin. The theoretical percentage of water in azithromycin monohydrate is 2.3%. However, Canadian Patent 1,314,876 reports a value of 3.92%, and a value of 3.2% is reported in Canadian patent 1,314,876. No reference to the percentage of water is made in the other above-mentioned Canadian patents. Azithromycin monohydrate is known to be hygroscopic (see for example European Patent 298 650 B1). This is an undesirable property since it complicates formulation of azithromycin drug product and can adversely effect its stability on long term storage.
Canadian patent 1,314,876 claims azithromycin dihydrate and, in contrast to azithromycin monohydrate, a full description of the drying process used for obtaining the product is provided. Low boiling, solvents (tetrahydrofuran and hexane) are used with 3-4 equivalent moles of water to obtain the crystalline product, which is dried under vacuum at low temperatures (20-10° C.). The use of low boiling solvents for crystallisation and low temperatures for vacuum drying of the product are prescribed presumably to control the desirable amount of water that must be evaporated to afford azithromycin dihydrate. Excess loss of water, caused by higher temperature vacuum drying, could result in the formation of azithromycin monohydrate. In contrast to anhydrous azithromycin and azithromycin monohydrate, azithromycin dihydrate has desirable properties for formulation. It is crystalline and can therefore be obtained in pure form in commercial scale. It is not hygroscopic and therefore does not pose a problem during formulation or adversely effect the stability of the resulting drug product.
It is clear that anhydrous and monohydrate forms of azithromycin are not suitable for formulation. The processes referred to in Canadian Patent 1 314 876 for the preparation of azithromycin dihydrate, while producing a non-hygroscopic form of azithromycin, have a number of disadvantages:
-
- 1. Water immiscibility of the organic solvent mixture (tetrahydrofuran plus hexane) can cause problems in obtaining pure material since crystallisation processes are known to afford pure material when the anti-solvent is miscible with the solvent used to dissolve the crude product.
- 2. The drying process must be very carefully controlled since an increase in temperature will cause the transformation of the non-hygroscopic dihydrate to the hygroscopic monohydrate.
- 3. The use of low boiling point solvents is complicated by their toxicity and possibility of formation of explosive peroxide during solvent recovery.
It has now been surprisingly found that slow addition of water to an isopropanol solution of azithromycin results in the formation of a new form of azithromycin, namely azithromycin monohydrate isopropanol clathrate of formula II:
The physical properties of this product and the processes used for its preparation have a number of major advantages over the existing azithromycin product forms and the procedures used for their preparation.
First, azithromycin monohydrate isopropanol clathrate is crystalline and, in contrast to anhydrous azithromycin, may be obtained in pure form.
Second, azithromycin monohydrate isopropanol clathrate is not hygroscopic and, in contrast to anhydrous azithromycin and azithromycin monohydrate, may be used in formulations of the drug product as tablets or capsules with excellent stability profiles.
Third, azithromycin monohydrate isopropanol clathrate is, in contrast to azithromycin dihydrate, obtained conveniently and reproducibly by crystallisation from isopropanol water.
Fourth, in contrast to azithromycin dihydrate, azithromycin monohydrate isopropanol clathrate is obtained by crystallisation from inexpensive solvents.
Fifth, in contrast to azithromycin dihydrate, azithromycin monohydrate isopropanol clathrate is prepared from environmentally safe solvents (hexane: Class 2; isopropanol and tetrahydrofuran: Class 3, see Federal Register, Vol. 62, No. 247, 67381, Dec. 24, 1997).
Sixth, the experimental conditions are simple and applicable to large-scale production.
Seventh, the present processes are reproducible in a wide spectrum of physical conditions and consistently afford azithromycin monohydrate isopropanol clathrate with a constant ratio of azithromycin, water and isopropanol (vacuum drying at 1-10 mm Hg at 500 to 60° C. for 12 to 24 hours).
Eighth, the product generated by the processes of the present invention is highly pure.
Ninth, the processes taught in this invention afford high yields of the product within the range of 88% to 93% (first crop). The remainder of the product is conveniently recovered from the mother liquor by evaporation of isopropanol under reduced pressure.
BRIEF DESCRIPTION OF THE INVENTIONIn one aspect, the invention relates to a compound of formula II:
In another aspect, the invention relates to a process for the preparation of azithromycin monohydrate isopropanol clathrate which comprises the steps of:
-
- (a) Dissolving azithromycin in isopropanol and slowly adding water to the resulting solution;
- (b) Filtering and washing the product with a mixture of isopropanol water;
- (c) Vacuum drying the product.
The present invention describes a new form of azithromycin monohydrate, namely azithromycin monohydrate isopropanol clathrate and the processes for the preparation of pure azithromycin monohydrate isopropanol clathrate.
Previously known forms of azithromycin (anhydrous, monohydrate, and dihydrate) may serve as the starting material in the present, all of which are commercially available.
According to this invention, azithromycin monohydrate isopropanol clathrate contains three molecules of isopropanol for every ten molecules of azithromycin monohydrate. The process comprises the dissolution of azithromycin in isopropanol to which water is added slowly while stirring, resulting in the precipitation of crystalline azithromycin monohydrate isopropanol clathrate. The volume of solvent used is such as to be sufficient to dissolve azithromycin. The addition of the water is carried out between 0° and 30° C. and preferably between 15° C. to 25° C. The product is filtered and washed with a mixture of water-isopropanol and dried under vacuum (1-10 mm Hg) at 50° C. to 60° C. for 12-24 hours to obtain azithromycin monohydrate isopropanol clathrate in high yields. Extension of vacuum drying does not reduce either the water content or the isopropanol content of azithromycin monohydrate isopropanol clathrate.
Elemental analysis, 1HNMR, 13C NMR, and IR spectroscopy, mass spectrometry, and powder x-ray diffraction and IR have identified the azithromycin monohydrate isopropanol clathrate produced according to the invention.
Differential Scanning Colorimetry (DSC) of azithromycin monohydrate (157.99° C.) and azithromycin monohydrate isopropanol clathrate (149.88° C.) are shown in
Near IR spectra of azithromycin monohydrate and azithromycin monohydrate isopropanol clathrate are shown in FIG. 7. The major difference is at 6800 cm−1 at which the clathrate shows a medium absorption.
The water content of azithromycin monohydrate isopropanol clathrate was measured by the Karl-Fischer method and its isopropanol content was determined by gas chromatography.
The invention will be more fully understood by the following examples, which illustrate the present invention, but are not to be considered limiting to the scope of the invention.
EXAMPLE 1Anhydrous azithromycin (1 kg ) is dissolved in isopropanol (2.8 kg) by warming. The solution is stirred vigorously and water (4.35 kg) is added slowly over a 1-hour period. The mixture is cooled to 20° C. and stirred for an additional 6 hours at this temperature. The resulting product is filtered and washed with a 40:60 mixture of isopropanol-water. The cake was then dried vacuum (6 to 10 mm Hg) at 50° C. for 12 hours. Yield 0.88 kg (88%).
EXAMPLE 2Azithromycin monohydrate (1 kg) is dissolved in isopropanol (2.8 kg) by warming. The solution is stirred vigorously and water (4.35 kg) is added slowly over a 1-hour period. The mixture is cooled to 20° C. and stirred for an additional 6 hours at this temperature. The resulting product is filtered and washed with a 40:60 mixture of isopropanol-water. The cake was then dried vacuum (6 to 10 mm Hg) at 50° C. for 12 hours. Yield 0.88 kg (88%).
EXAMPLE 3Azithromycin dihydrate (1 kg) is dissolved in isopropanol (2.8 kg) by warming. The solution is stirred vigorously and water (4.35 kg) is added slowly over a 1-hour period. The mixture is cooled to 20° C. and stirred for an additional 6 hours at this temperature. The resulting product is filtered and washed with a 40:60 mixture of isopropanol-water. The cake was then dried vacuum (6 to 10 mm Hg) at 50° C. for 12 hours. Yield 0.88 kg (88%).
Claims
1. A compound of formula II:
2. A process for the preparation of azithromycin monohydrate isopropanol clathrate which comprises the steps of:
- (a) dissolving azithromycin in isopropanol and slowly adding water to the resulting solution so that a precipitate of crystalline azithromycin monohydrate isopropanol clathrate is formed;
- (b) filtering and washing the product resulting from step (a) with a mixture of isopropanol and water; and
- (c) vacuum drying the product resulting from step (b).
3. The process of claim 2 wherein the dissolution of crystalline azithromycin is carved out in a volume of solvent only sufficient to dissolve the azithromycin.
4. The process of claim 2 wherein water is added over a period of one hour.
5. The process of claim 2 wherein the addition of water to the resulting solution is carried out between 0° C. to 30° C.
6. The process of claim 5 wherein the addition of water is carried between 15° C. to 25° C.
7. The process of claim 2 wherein vacuum drying is carried out at a temperature of 50° C. to 60° C.
8. The process of claim 2 wherein the vacuum drying is carried out under 6 to 10 mm Hg.
9. A process for the preparation of azithromycin monohydrate isopropanol clathrate characterised by the following x-ray powder diffraction pattern expressed in terms of “D” spacings and Relative Intensity: which comprises the steps of:
- Relative Intensity Angle (°2θ) D-value (Å) % 4.985 17.712 0.2 5.605 15.754 0.3 6.205 14.232 1.3 7.350 12.017 1.7 7.835 11.246 7.5 8.247 10.721 0.4 8.830 10.006 0.3 9.400 9.401 4.1 9.790 9.027 100.0 10.245 6.627 0.4 11.165 7.918 8.8 11.365 7.779 2.5 11.935 7.409 1.4 12.495 7.078 4.3 13.055 6.341 2.2 14.250 6.210 1.2 14.645 6.044 2.6 14.810 3.977 1.8 15.270 5.798 3.3 15.700 5.640 2.9 15.990 5.338 0.9 16.595 5.338 1.1 17.040 5.199 2.1 17.450 5.078 1.5 18.035 4.915 0.5 18.375 4.824 1.0 18.540 4.782 1.0 19.060 4.613 2.8 19.670 4.510 2.8 19.995 4.437 1.7 20.425 4.315 2.7 20.885 4.150 1.1 21.030 4.221 0.8 21.740 4.085 0.8 22.540 3.941 0.8 23.470 3.787 0.5 24.125 3.680 0.6 24.475 3.634 0.7 24.705 3.601 0.7 25.245 3.525 0.6 25.510 3.489 0.9 26.145 1.406 0.8 26.510 3.360 0.2 28.320 3.145 0.3 29.200 3.056 0.3 29.410 3.035 0.3 29.825 2.993 0.2 32.750 2.732 0.4 33.565 2.668 0.4 34.640 2.587 0.2 35.295 2.541 0.3 36.133 2.484 0.3 37.490 2.397 0.2 39.710 2.268 0.2
- (a) dissolving azithromycin in isopropanol and slowly adding water to the resulting solution so that a precipitate of crystalline azithromycin monohydrate isopropanol clathrate is formed;
- (b) filtering and washing the product resulting from step (a) with a mixture of isopropanol and water; and
- (c) vacuum drying the product resulting from step (b).
10. The compound of claim 1 which is pure.
11. The compound of claim 10 which is free of azithromycin dihydrate.
12. The compound of claim 1 formulated as a drug product.
13. The compound of claim 12 in tablet form.
14. The compound of claim 12 in capsule form.
15. Crystalline azithromycin monohydrate isopropanol clathrate.
16. The compound of claim 15 which is pure.
17. The compound of claim 16 which is free of azithromycin dihydrate.
18. The compound of claim 15 formulated as a drug product.
19. The compound of claim 18 in tablet form.
20. The compound of claim 18 in capsule form.
21. Azithromycin monohydrate isopropanol clathrate characterized by the x-ray diffraction pattern as illustrated in FIG. 3.
22. The compound of claim 21 which is pure.
23. The compound of claim 22 which is free of azithromycin dihydrate.
24. The compound of claim 21 formulated as a drug product.
25. The compound of claim 24 in tablet form.
26. The compound of claim 24 in capsule form.
27. The compound of claim 21 wherein the DSC thereof is illustrated in FIG. 6.
28. The compound of claim 21 further characterized by the IR spectrum thereof as illustrated in FIG. 7
29. The compound of claim 28 further characterized by the DSC thereof illustrated in FIG. 6.
30. Azithromycin monohydrate isopropanol clathrate characterized by the IR spectrum thereof as illustrated in FIG. 7.
31. The compound of claim 30 wherein the DSC thereof is illustrated in FIG. 6.
32. The compound of claim 30 which is pure.
33. The compound of claim 32 which is free of azithromycin dihydrate.
34. The compound of claim 30 formulated as a drug product.
35. The compound of claim 34 in tablet form.
36. The compound of claim 34 in capsule form.
37. Azithromycin monohydrate isopropanol clathrate characterized by the following x-ray powder diffraction pattern expressed in terms of “D” spacings and Relative Intensity:
- Relative Intensity Angle (°2θ) D-value (Å) % 4.986 17.712 0.2 5.605 15.754 0.3 6.205 14.232 1.3 7.350 12.017 1.7 7.855 11.246 7.5 8.240 10.721 0.4 8.830 10.006 0.3 9.400 9.401 4.1 9.790 9.017 100.0 10.245 4.827 0.4 11.165 7.918 8.8 11.368 7.779 2.5 11.938 7.409 1.4 12.485 7.078 4.3 13.935 6.941 2.2 14.250 6.210 2.3 14.545 6.044 2.6 14.810 1.977 1.8 15.270 5.640 1.9 16.595 1.378 1.1 17.040 5.199 2.1 17.450 5.078 2.5 18.375 4.284 1.0 18.340 4.782 1.0 19.080 4.510 2.8 19.995 4.437 1.9 20.425 4.349 2.7 20.889 4.150 1.1 21.050 4.321 0.8 21.740 4.085 0.8 22.540 3.941 0.8 23.470 3.787 0.5 24.475 1.634 0.7 24.705 3.801 0.7 25.245 3.525 0.4 25.510 1.489 0.9 25.149 3.406 0.8 26.510 3.360 0.3 28.320 3.145 0.3 29.200 3.096 0.3 29.410 3.039 0.3 29.829 2.993 0.2 30.170 2.960 0.2 32.150 2.732 0.4 33.365 2.668 0.4 34.640 2.587 0.3 35.291 2.541 0.3 36.135 2.484 0.3 37.490 2.397 0.2 39.710 2.268 0.2.
38. The compound of claim 37 which is pure.
39. The compound of claim 38 which is free of azithromycin dihydrate.
40. The compound of claim 37 formulated as a drug product.
41. The compound of claim 40 in tablet form.
42. The drug product of claim 40 in capsule form.
| 1191843 | August 1985 | CA |
| 1202619 | April 1986 | CA |
| 1202626 | April 1986 | CA |
| 1202963 | April 1986 | CA |
| 1314876 | July 1988 | CA |
| 2 245 398 | January 2002 | CA |
| 1093370 | October 1994 | CN |
| 0 298 650 | January 1989 | EP |
| 0 298 650 | January 1989 | EP |
| 0 298 650 | January 1992 | EP |
| 0 298 650 | February 1992 | EP |
| 1 103 558 | May 2001 | EP |
| 1 103 558 | July 2001 | EP |
| WO 98/04574 | February 1998 | WO |
| WO 00/14099 | March 2000 | WO |
| WO 00/32203 | June 2000 | WO |
| WO 01/00640 | January 2001 | WO |
- Federal Register, vol. 62, No. 247, 67381, Dec. 25, 1997.
- International Search Report for Published Application No. WO 02/094843 A1, Application No. PCT/IB 02/01570; pp. 1-6.
Type: Grant
Filed: Jun 5, 2003
Date of Patent: May 2, 2006
Assignee: Apotex, Inc. (Thornill)
Inventors: Khashayar Karimian (Toronto), Mehrnoush Motamedi (Norcross, GA)
Primary Examiner: Elli Peselev
Attorney: Welsh & Katz, Ltd.
Application Number: 10/454,586
International Classification: A61K 31/70 (20060101); C07H 1/00 (20060101); C07H 17/08 (20060101);
